Table 1. Descriptive data of patients included in the study stratified by histological type of primary tumor.
| p Stage | N (%) | Age range (years) | Mean age (year) | Female sex | Mean diameter (cm) | Iodotherapy | Cervical recurrence | Distant metastasis | Disease persistence | Alive (disease free) | Alive (with disease) | Death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Papillary carcinoma (N = 679) | ||||||||||||
|
| ||||||||||||
| pT1a N0 | 205 (30.2%) | 20-82 | 52.7 | 184 (89.8%) | 0.5 | 28 (13.66%) | 7 (3.4%) | 0 (0.0%) | 0 (0.0%) | 203 (99.0%) | 2 (0.8%) | 0 (0.0%) |
| pT1b N0 | 88 (13.0%) | 20-78 | 49.6 | 75 (85.2%) | 1.4 | 57 (64.77%) | 10 (11.4%) | 3 (3.4%) | 0 (0.0%) | 83 (94.3%) | 3 (3.4%) | 2 (2.27%) |
| pT1a N1a | 8 (1.2%) | 21-48 | 34.6 | 6 (75.0%) | 0.5 | 5 (62.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 8 (100.0%) | 0 (0.0%) | 0 (0.0%) |
| pT1a N1b | 6 (0.9%) | 26-68 | 47.0 | 5 (83.3%) | 0.8 | 6 (100.0%) | 2 (33.3%) | 0 (0.0%) | 0 (0.0%) | 6 (100.0%) | 0 (0.0%) | 0 (0.0%) |
| pT1b N1a | 10 (1.5%) | 20-71 | 42.5 | 8 (80.0%) | 1.5 | 9 (90.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 10 (100.0%) | 0 (0.0%) | 0 (0.0%) |
| pT1b N1b | 9 (1.3%) | 21-50 | 37.3 | 6 (66.7%) | 1.5 | 9 (100.0%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 8 (88.9%) | 0 (0.0%) | 1 (11.11%) |
| pT2 N0 | 48 (7.1%) | 22-84 | 48.8 | 42 (87.5%) | 2.8 | 40 (83.33%) | 4 (8.3%) | 1 (2.1%) | 0 (0.0%) | 47 (97.9%) | 1 (2.1%) | 0 (0.0%) |
| pT2 N1a | 7 (1.0%) | 14-87 | 39.7 | 4 (57.1%) | 2.3 | 7 (100.0%) | 3 (42.9%) | 0 (0.0%) | 0 (0.0%) | 5 (71.4%) | 2 (28.6%) | 0 (0.0%) |
| pT2 N1b | 5 (0.7%) | 22-72 | 50.2 | 3 (60.0%) | 2.5 | 4 (57.14%) | 1 (20.0%) | 1 (20.0%) | 0 (0.0%) | 5 (100.0%) | 0 (0.0%) | 0 (0.0%) |
| pT3 N0 | 141 (20.8%) | 18-87 | 51.9 | 121 (85.8%) | 2.3 | 122 (86.52%) | 10 (7.1%) | 6 (4.3%) | 0 (0.0%) | 132 (93.6%) | 7 (5.0%) | 1 (0.71%) |
| pT3 N1a | 37 (5.4%) | 19-80 | 46.8 | 34 (91.9%) | 2.3 | 37 (100.0%) | 12 (32.4%) | 4 (10.8%) | 0 (0.0%) | 30 (81.1%) | 4 (10.8%) | 3 (8.11%) |
| pT3 N1b | 39 (5.7%) | 20-73 | 46.4 | 33 (84.6%) | 3.0 | 36 (92.30%) | 11 (28.2%) | 5 (12.8%) | 1 (2.6%) | 27 (69.2%) | 11 (28.2%) | 1 (2.57%) |
| pT4aN0 | 7 (1.0%) | 22-81 | 50.3 | 4 (57.1%) | 6.7 | 7 (100.0%) | 1 (14.3%) | 3 (42.9%) | 0 (0.0%) | 6 (85.7%) | 1 (14.3%) | 0 (0.0%) |
| pT4a N1a | 8 (1.2%) | 44-65 | 58.0 | 5 (62.5%) | 5.0 | 8 (100.0%) | 1 (12.5%) | 3 (37.5%) | 3 (37.5%) | 3 (37.5%) | 4 (50.0%) | 1 (12.5%) |
| pT4a N1b | 14 (2.1%) | 13-69 | 42.3 | 8 (57.1%) | 4.5 | 12 (85.71%) | 9 (64.3%) | 4 (28.6%) | 3 (21.4%) | 6 (42.9%) | 6 (42.9%) | 2 (14.28%) |
| pT4b N0 | 3 (0.4%) | 43, 54, 73 | 56.7 | 2 (66.7%) | 9.8 | 2 (66.67%) | 3 (100.0%) | 2 (66.7%) | 3 (100.0%) | 0 (0.0%) | 2 (66.7%) | 1 (33.33%) |
| pT4b N1a | 2 (0.3%) | 4, 64 | 52.5 | 1 (50.0%) | 8.0 | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) |
| pT4b N1b | 2 (0.3%) | 50, 70 | 60.0 | 0 (0.0%) | 5.0 | 1 (50.0%) | 0 (0.0%) | 2 (100.0%) | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) |
| Missing stage | 40 (5.9%) | 19-78 | 47.7 | 31 (77.5%) | - | 27 (67.50%) | 12 (30.0%) | 14 (2.1%) | 5 (12.5%) | 15 (37.5%) | 22 (55.0%) | 3 (7.50%) |
| Total | 679 (83.72%) | 20-84 | 48.2 | 572 (84.24%) | 3.4 | 419 (61.71%) | 87 (12.81%) | 50 (7.36%) | 19 (2.80%) | 594 (87.48%) | 67 (9.87%) | 16 (2.36%) |
|
| ||||||||||||
| Follicular carcinoma (N = 61) | ||||||||||||
|
| ||||||||||||
| pT1 N0 | 10 (16.4%) | 31-82 | 58.0 | 9 (90.0%) | 1.4 | 5 (50.0%) | 1 (10.0%) | 3 (30.0%) | 0 (0.0%) | 7 (70%) | 2 (20%) | 1 (10%) |
| pT1 N1a | 1 (1.6%) | 38 | 38.0 | 1 (100.0%) | 1.5 | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
| pT2 N0 | 13 (21.3%) | 19-75 | 48.8 | 11 (84.6%) | 2.5 | 10 (76.9%) | 0 (0.0%) | 2 (15.4%) | 1 (76.9%) | 11 (84.6%) | 2 (15.4%) | 0 (0.0%) |
| pT3 N0 | 12 (19.7%) | 32-81 | 60.5 | 10 (83.3%) | 4.2 | 12 (100.0%) | 2 (16.7%) | 5 (41.7%) | 0 (0.0%) | 7 (58.3%) | 4 (33.3%) | 1 (8.3%) |
| pT3 N1a | 2 (3.3%) | 70-73 | 71.5 | 2 (100.0%) | 7.3 | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) |
| pT3 N1b | 1 (1.6%) | 76 | 76.0 | 0 (0.0%) | 10.5 | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
| pT4 N0 | 2 (3.3%) | 61, 75 | 68.0 | 1 (50.0%) | 6.1 | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) |
| pT4 N1 | 2 (3.3%) | 39, 69 | 54.0 | 2 (100.0%) | 2.4 | 2 (100.0%) | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) |
| Missing stage | 18 (29.5%) | 39-84 | 64.4 | 12 (66.7%) | - | 9 (50.0%) | 5 (27.8%) | 11 (61.1%) | 4 (22.2%) | 3 (16.7%) | 12 (66.7%) | 2 (11.1%) |
| Total | 61 (7.52%) | 19-84 | 59.9 | 48 (78.69%) | 4.5 | 43 (70.49%) | 12 (19.67%) | 26 (42.62%) | 6 (9.83%) | 29 (47.54%) | 25 (40.98%) | 7 (11.47%) |
|
| ||||||||||||
| Medulary carcinoma (N = 54) | ||||||||||||
|
| ||||||||||||
| pT1 N0 | 2 (3.7%) | 37, 52 | 44.5 | 2 (100.0%) | 0.6 | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) |
| pT1 N1b | 5 (9.3%) | 16-66 | 37.4 | 2 (40.0%) | 1.1 | 2 (40.0%) | 2 (40.0%) | 3 (60.0%) | 4 (80.0%) | 1 (20.0%) | 3 (60.0%) | 1 (20.0%) |
| pT2 N0 | 3 (5.6%) | 47, 56, 66 | 56.3 | 3 (100.0%) | 3.4 | 1 (33.3%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 2 (66.7%) | 1 (33.3%) | 0 (0.0%) |
| pT2 N1b | 4 (7.4%) | 13-61 | 31.8 | 4 (100.0%) | 3.5 | 2 (50.0%) | 2 (50.0%) | 2 (50.0%) | 3 (75.0%) | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) |
| pT3 N1b | 10 (18.5%) | 8-72 | 53.8 | 4 (40.0%) | 4.0 | 5 (50.0%) | 0 (0.0%) | 8 (80.0%) | 10 (100.0%) | 0 (0.0%) | 9 (90.0%) | 1 (10.0%) |
| pT4a N1b | 11 (20.4%) | 21-72 | 42.3 | 5 (45.5%) | 4.5 | 6 (54.5%) | 0 (0.0%) | 9 (81.8%) | 11 (100.0%) | 0 (0.0%) | 9 (81.8%) | 2 (18.2%) |
| Missing stage | 19 (35.2%) | 14-78 | 41.1 | 11 (57.9%) | - | 11 (57.9%) | 6 (31.6%) | 14 (73.7%) | 12 (63.2%) | 0 (0.0%) | 16 (84.2%) | 3 (15.8%) |
| Total | 54 (6.66%) | 8-78 | 43.9 | 31 (57.40%) | 2.9 | 27 (50.00%) | 11 (20.37%) | 37 (68.52%) | 40 (68.96%) | 4 (7.41%) | 43 (79.63%) | 7 (11.86%) |
|
| ||||||||||||
| Poorly differentiated carcinoma (N = 11) | ||||||||||||
|
| ||||||||||||
| pT2 N0 | 1 (9.1%) | 72 | 72.0 | 1 (100.0%) | 2.5 | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) |
| pT2 N1 | 1 (9.1%) | 44 | 44.0 | 1 (100.0%) | 3.0 | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) |
| pT3 N0 | 2 (18.2%) | 63, 67 | 65.0 | 0 (0.0%) | 8.4 | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) |
| p T4a N1b | 5 (45.5%) | 49, 84 | 60.6 | 3 (60.0%) | 8.7 | 3 (60.0%) | 0 (0.0%) | 1 (20.0%) | 5 (100.0%) | 0 (0.0%) | 4 (80.0%) | 1 (20.0%) |
| pT4b | 1 (9.1%) | 72 | 72.0 | 1 (100.0%) | 6.0 | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) |
| Missing stage | 1 (9.1%) | 44 | 44.0 | 1 (100.0%) | - | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
| Total | 11 (1.36%) | 44-84 | 59.6 | 7 (63.64%) | 5.7 | 8 (72.72%) | 3 (27.27%) | 5 (45.45%) | 9 (81.82%) | 1 (9.09%) | 5 (45.45%) | 4 (36.36%) |
|
| ||||||||||||
| Anaplastic carcinoma (N = 6) | ||||||||||||
|
| ||||||||||||
| IV B | 2 (33.3%) | 66, 74 | 70.0 | 1 (50.0%) | - | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) |
| IV C | 4 (66.7%) | 44-72 | 57.8 | 1 (25%) | - | 3 (75.0%) | - | 4 (100.0%) | 4 (100.0%) | 0 (0.0%) | 2 (50.0%) | 2 (50.0%) |
| Total | 6 (0.74%) | 44-74 | 63.0 | 2 (33.33%) | - | 3 (50.00%) | 0 (0.00%) | 66.67% | 6 (100.00%) | 0.00% | 33.33% | 66.67% |